Retrieved March 10, 2026, from After adding coverage of GLP-1s for weight loss August 1, 2024, North Carolina Medicaid reversed course to end coverage effective October 1, 2025, due to North Carolina Department of Health and Human Services (DHHS) anticipated shortfalls in state funding prompted by budget disagreements in the North Carolina General Assembly
Rosacea has been linked with: SIBO (small intestinal bacterial overgrowth) Dysbiosis H
doi: 10.1080/21655979.2022.2049471 187 Truong DoMGyun KimHHo ChoiJGwang JeongH
All animal experiments were conducted in accordance with the Guide to Academic Integrity and Research Ethics issued by the Supreme Council of Universities (SCU), Egypt, the institutional guidelines and regulations for the care and use of experimental animals, and the relevant national ethical standards
Based on Phase 2 data, retatrutide's side effect profile is consistent with the GLP-1 class: nausea, vomiting, diarrhea, and constipation, most prominent during dose escalation and typically resolving over time